(HealthDay News) — Racial and ethnic disparities are seen in the use of obesity management medications, according to a study published online Dec. 17 in the Journal of Racial and Ethnic Health ...

(HealthDay News) — Vaccines to protect against respiratory syncytial virus (RSV) in newborns and older adults are being more ...

Significant reductions seen in birth weight with exposure to certain DMTs, and increase seen in rate of small for gestational age ...

An expert panel consisting of dietitians, doctors, nutritional epidemiologists, chefs, and weight loss researchers examined ...

Eight-point-eight percent decrease seen in volume of patient-initiated medical advice message threads in six months after implementation ...

Antiretroviral therapy recommended for all individuals with HIV; recommendations provided for those with specific clinical circumstances ...

Vaccine effectiveness of 52.8% seen for ED visits, 52.3% for noncritical hospitalization, 50.4% for critical hospitalization.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under Priority Review for avutometinib, in combination with defactinib, for the treatment of adults with ...

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.

The Company has been granted Competitive Generic Therapy designation, which allows for 180 days of marketing exclusivity.

The phase 3 STEER study enrolled 127 treatment-naïve patients aged 2 to less than 18 years with SMA type 2 who were able to sit but had never walked independently.